JP7281795B2 - 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法 - Google Patents

膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法 Download PDF

Info

Publication number
JP7281795B2
JP7281795B2 JP2018552212A JP2018552212A JP7281795B2 JP 7281795 B2 JP7281795 B2 JP 7281795B2 JP 2018552212 A JP2018552212 A JP 2018552212A JP 2018552212 A JP2018552212 A JP 2018552212A JP 7281795 B2 JP7281795 B2 JP 7281795B2
Authority
JP
Japan
Prior art keywords
trail
peg
composition
pancreatitis
pancreatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018552212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511515A (ja
JP2019511515A5 (OSRAM
Inventor
ソルキ リー，
マーティン ジー． ポンパー，
オギ パク，
マグダレーナ スヴィエルシェヴスキ，
パンカジ ジェイ． パスリチャ
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2019511515A publication Critical patent/JP2019511515A/ja
Publication of JP2019511515A5 publication Critical patent/JP2019511515A5/ja
Priority to JP2022031685A priority Critical patent/JP2022066353A/ja
Application granted granted Critical
Publication of JP7281795B2 publication Critical patent/JP7281795B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2018552212A 2016-04-07 2017-04-07 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法 Active JP7281795B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022031685A JP2022066353A (ja) 2016-04-07 2022-03-02 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662319454P 2016-04-07 2016-04-07
US62/319,454 2016-04-07
PCT/US2017/026617 WO2017177148A1 (en) 2016-04-07 2017-04-07 Compositions and methods for treating pancreatitis and pain with death receptor agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022031685A Division JP2022066353A (ja) 2016-04-07 2022-03-02 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019511515A JP2019511515A (ja) 2019-04-25
JP2019511515A5 JP2019511515A5 (OSRAM) 2020-05-07
JP7281795B2 true JP7281795B2 (ja) 2023-05-26

Family

ID=58632624

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018552212A Active JP7281795B2 (ja) 2016-04-07 2017-04-07 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
JP2022031685A Withdrawn JP2022066353A (ja) 2016-04-07 2022-03-02 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022031685A Withdrawn JP2022066353A (ja) 2016-04-07 2022-03-02 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法

Country Status (9)

Country Link
US (1) US11084879B2 (OSRAM)
EP (1) EP3439687A1 (OSRAM)
JP (2) JP7281795B2 (OSRAM)
KR (1) KR102508650B1 (OSRAM)
CN (1) CN109195620B (OSRAM)
AU (1) AU2017248264B2 (OSRAM)
CA (1) CA3020339C (OSRAM)
EA (1) EA201892260A1 (OSRAM)
WO (1) WO2017177148A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113424795B (zh) * 2021-05-24 2022-09-09 四川大学华西医院 一种急性胰腺炎动物模型的构建方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164217A1 (en) 2014-04-21 2015-10-29 Theraly Pharmaceuticals Inc. Trail receptor agonists for treatment of fibrotic diseases

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
EP1666591B1 (en) 1995-06-29 2011-03-23 Immunex Corporation Cytokine that induces apoptosis
CN1168495C (zh) 1997-01-15 2004-09-29 凤凰药理学公司 被修饰的肿瘤坏死因子
EP1012274B2 (en) 1997-01-28 2011-06-15 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
EP1001990A4 (en) 1997-06-26 2001-12-19 Immunex Corp PROTEIN BINDING TO TRAIL PROTEIN
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6329148B1 (en) 1999-02-16 2001-12-11 The Board Of Trustees Of The Leland Stanford University Combined therapy of diterpenoid triepoxides and death domain receptor ligands for synergistic killing of tumor cells
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
DK1180121T3 (da) 1999-05-17 2004-03-01 Conjuchem Inc Langtidsvirkende insulinotrope peptider
CA2386002A1 (en) 1999-09-30 2001-04-05 The Trustees Of The University Of Pennsylvania Trail: an inhibitor of autoimmune inflammation and cell cycle progression
IL136156A0 (en) 2000-05-16 2001-05-20 Compugen Ltd Sequences of trail variants
US20040005314A1 (en) 2001-07-27 2004-01-08 Enrique Escandon Apo-2l receptor agonist and cpt-11 synergism
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
WO2002022212A2 (en) 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
KR20020056565A (ko) 2000-12-29 2002-07-10 황규언 인간유래 세포 소멸 인자와 그 수용체의 결합체인ＴＲＡＩＬ-ｓＤＲ5 결합체의 결정화에 의한 3차원 구조및 ＴＲＡＩＬ 결실 돌연변이 단백질
US20020169123A1 (en) 2001-02-27 2002-11-14 The Trustees Of The University Of Pennsylvania Regulating apoptosis in TRAIL-resistant cancer cells, while protecting normal, non-cancerous cells
EP1275378B1 (en) 2001-07-10 2009-04-15 Canon Kabushiki Kaisha Particulate construct comprising polyhydroxyalkanoate and method for producing it
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
IL161051A0 (en) 2001-10-02 2004-08-31 Genentech Inc Apo-2 ligand variants and uses thereof
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7906118B2 (en) 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
WO2004009774A2 (en) 2002-07-19 2004-01-29 Amgen Inc. Protein conjugates with a water-soluble biocompatible, biogradable polymer
EP1539210A4 (en) 2002-09-06 2006-06-07 Bayer Pharmaceuticals Corp GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2004039307A2 (en) 2002-10-30 2004-05-13 Pfizer Products Inc. Methods and compositions for diagnosing and treating companion animal cancer
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
ES2274480T3 (es) 2003-05-09 2007-05-16 Genentech, Inc. Peptidos ligando el receptor de apo-2l y sus usos.
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7795404B1 (en) 2003-08-08 2010-09-14 Five Prime Therapeutics, Inc. Human soluble notch receptor ligands
GB0328261D0 (en) 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
US8003111B2 (en) 2005-04-06 2011-08-23 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
US8034352B2 (en) 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
RU2395294C2 (ru) 2004-06-18 2010-07-27 Дженентек, Инк. Способы применения агонистов аро-2l-рецепторов и активаторов nk-клеток
EP1773400A2 (en) 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
US20060046961A1 (en) 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
NZ553174A (en) 2004-09-08 2010-03-26 Genentech Inc Methods of using death receptor ligands Apo2L/Trail and CD20 antibodies
WO2006042848A2 (en) 2004-10-18 2006-04-27 Novo Nordisk A/S Growth hormone conjugates
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
EP1695717A1 (en) 2005-02-23 2006-08-30 Ludwig-Maximilians-Universität Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells
US20060228352A1 (en) 2005-02-24 2006-10-12 Schoenberger Stephen P TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
AU2006232310B9 (en) 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
CN101484182B (zh) 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
US8158129B2 (en) 2005-04-06 2012-04-17 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
EP1745802A1 (en) 2005-07-20 2007-01-24 Kreatech Biotechnology B.V. Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
EP1937851A4 (en) 2005-10-19 2010-08-25 Ibc Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR PRODUCING BIOACTIVE GROUPS OF INCREASED COMPLEXITY AND THEIR USE
GB0524316D0 (en) 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
AU2007239095B2 (en) 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
KR100784485B1 (ko) 2006-01-18 2007-12-11 한국과학기술연구원 생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도
WO2007102690A1 (en) 2006-03-06 2007-09-13 Postech Foundation Vector including the codon-optimized dna cassette for producing secretory recombinant dodecamer trail
KR100746962B1 (ko) 2006-04-04 2007-08-07 한국과학기술연구원 온도 감응성 포스파젠계 고분자-생리 활성 물질 복합체,그의 제조방법 및 그의 용도
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
KR100886783B1 (ko) 2006-06-12 2009-03-04 성균관대학교산학협력단 N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
EP2044434B1 (en) 2006-06-20 2015-11-18 Genentech, Inc. Methods and materials for observing apoptosis by detecting fragments of clathrin-pathway components
ATE520032T1 (de) 2006-06-21 2011-08-15 Apogenix Gmbh Differentielle cytokinexpression bei einer menschlichen krebserkrankung
WO2008088582A2 (en) 2006-08-04 2008-07-24 Mayo Foundation For Medical Education And Research Methods and materials related to trail isoforms
AU2007292295B2 (en) 2006-09-06 2013-06-06 Immunoforge Co., Ltd. Fusion peptide therapeutic compositions
WO2008120832A1 (en) 2007-03-30 2008-10-09 Industry-Academic Cooperation Foundation, Yonsei University Human neural stem cell secreting a smac, preparation method and use thereof
WO2008130066A1 (en) 2007-04-20 2008-10-30 Kang Choon Lee Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
KR100968591B1 (ko) 2007-06-14 2010-07-08 한국과학기술연구원 약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도
US8986684B2 (en) 2007-07-25 2015-03-24 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
KR20100046185A (ko) 2007-08-09 2010-05-06 다이이찌 산쿄 가부시키가이샤 데스 도메인 함유 수용체 발현 세포에 아포토시스를 유도하는 이뮤노리포솜
MX2010004400A (es) 2007-10-23 2010-05-20 Nektar Therapeutics Polimeros de multiples brazos dirigidos a la hidroxiapatita y conjugados de estos.
AU2008319298B2 (en) 2007-10-31 2014-07-31 Medimmune, Llc Protein scaffolds
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
CN102119175A (zh) 2008-04-10 2011-07-06 Ibc药品公司 采用停靠与锁(dnl)技术制备具有增强的药物动力学的四聚细胞因子的模块方法
WO2009140469A2 (en) 2008-05-14 2009-11-19 Genentech, Inc. Methods of using apo2l/trail to treat cancer
US20100068302A1 (en) 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
GB0818649D0 (en) 2008-10-10 2008-11-19 Nat Univ Ireland Treatment of proliferative disorders with trail
US20120021995A1 (en) 2008-10-10 2012-01-26 Anaphore, Inc. Polypeptides that Bind TRAIL-R1 and TRAIL-R2
AU2009303304A1 (en) 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind TRAIL-RI and TRAIL-R2
EP3178835B1 (en) 2009-02-03 2019-04-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
PL3939617T3 (pl) 2009-02-13 2025-03-17 Immunomedics, Inc. Związki pośrednie do wytwarzania koniugatów z wiązaniem rozszczepialnym wewnątrzkomórkowo
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
AU2010286642B2 (en) 2009-08-31 2016-03-10 Ibc Pharmaceuticals, Inc. Bispecific immunocytokine dock-and-lock (DNL) complexes and therapeutic use thereof
WO2011079293A1 (en) 2009-12-23 2011-06-30 Ambrx, Inc Tumor necrosis factor-related apoptosis inducing ligand polypeptides and their uses
WO2011080314A2 (en) 2009-12-31 2011-07-07 Deutsches Krebsforschungszentrum Novel modulators of trail signalling
WO2011106707A2 (en) 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
BR112012026003B1 (pt) 2010-04-13 2022-03-15 Medimmune, Llc Estrutura multimérica recombinante específica trail r2, seu uso, bem como composição
US8461311B2 (en) 2010-06-08 2013-06-11 Washington University TRAIL trimers, methods and uses therefor
KR101209266B1 (ko) 2010-06-30 2012-12-06 한국과학기술연구원 생분해성 및 온도 감응성 폴리포스파젠계 자성 고분자, 그의 제조 방법 및 용도
MX344200B (es) 2010-10-29 2016-12-08 Daiichi Sankyo Co Ltd Novedoso anticuerpo anti-dr5.
EP2468764A1 (en) 2010-12-24 2012-06-27 Rijksuniversiteit te Groningen TNF family ligand variants
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
EP2681238A2 (en) 2011-02-28 2014-01-08 Istituto di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo- Ospedale di Alta Specializzazione E di Rilievo Apoptosis-inducing molecules and uses therefor
WO2012122514A1 (en) 2011-03-09 2012-09-13 Centrose, Llc Extracellular targeted drug conjugates
AU2012228100B2 (en) 2011-03-17 2016-09-08 The University Of Birmingham Re-directed immunotherapy
US20130101553A1 (en) 2011-04-18 2013-04-25 The Regents Of The University Of California Inducing inactivation of fibrogenic myofibroblasts
WO2012149546A2 (en) 2011-04-29 2012-11-01 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
EP2704735A1 (en) 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
FI20115640A0 (fi) 2011-06-22 2011-06-22 Turun Yliopisto Yhdistelmähoito
US8586020B2 (en) 2011-06-30 2013-11-19 Korea Institute Of Science And Technology Poly(organophosphazene) composition for biomaterials
EP2717917B1 (en) 2011-07-05 2016-04-20 biOasis Technologies Inc P97-antibody conjugates
CN111635462A (zh) 2011-07-06 2020-09-08 江苏靶标生物医药研究所有限公司 一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用
CN102898526A (zh) 2011-07-28 2013-01-30 山东先声麦得津生物制药有限公司 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
HK1206760A1 (en) 2012-03-28 2016-01-15 Amgen Inc. Dr5 receptor agonist combinations
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
CN104755936B (zh) 2012-08-30 2018-04-27 图尔库大学 选择个性化脑癌疗法的方法
CN109999195A (zh) 2012-09-20 2019-07-12 莫弗系统股份公司 类风湿关节炎的治疗
US20140134647A1 (en) 2012-11-01 2014-05-15 La Jolla Institute For Allergy And Immunology Novel crystal structure and ligand binding sites of trail receptor
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
US20150301058A1 (en) 2012-11-26 2015-10-22 Caris Science, Inc. Biomarker compositions and methods
WO2014121093A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
JP6177937B2 (ja) 2013-02-13 2017-08-09 エイジェンシー フォー サイエンス，テクノロジー アンド リサーチ 活性薬剤の放出のためのポリマーシステム
CN104342444B (zh) 2013-07-23 2017-11-17 四川大学华西医院 一种重组trail蛋白及其制备方法和用途
EP3041846B1 (en) 2013-09-02 2018-11-07 Hangzhou Dac Biotech Co., Ltd Novel cytotoxic agents for conjugation of drugs to cell binding molecule
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
PL222795B1 (pl) 2013-12-22 2016-09-30 Univ Warszawski Rekombinowane białko fuzyjne ProSTAT do zastosowania w leczeniu
PT3122757T (pt) 2014-02-28 2023-11-03 Hangzhou Dac Biotech Co Ltd Ligantes carregados e as suas utilizações em conjugação
US11299528B2 (en) * 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
US9901620B2 (en) * 2014-04-21 2018-02-27 Theraly Pharmaceuticals, Inc. Trail receptor agonists for treatment of fibrotic disease
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164217A1 (en) 2014-04-21 2015-10-29 Theraly Pharmaceuticals Inc. Trail receptor agonists for treatment of fibrotic diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
膵臓、２００８、Ｖｏｌ．２３，第１２４－１３１頁

Also Published As

Publication number Publication date
KR102508650B1 (ko) 2023-03-13
CN109195620A (zh) 2019-01-11
US20190119394A1 (en) 2019-04-25
CN109195620B (zh) 2022-06-28
AU2017248264A1 (en) 2018-10-18
EP3439687A1 (en) 2019-02-13
CA3020339C (en) 2022-05-03
AU2017248264B2 (en) 2020-01-30
CA3020339A1 (en) 2017-10-12
JP2019511515A (ja) 2019-04-25
KR20180129919A (ko) 2018-12-05
JP2022066353A (ja) 2022-04-28
WO2017177148A1 (en) 2017-10-12
EA201892260A1 (ru) 2019-03-29
US11084879B2 (en) 2021-08-10

Similar Documents

Publication Publication Date Title
RU2016122957A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
JP6825181B2 (ja) 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用
JP6339231B2 (ja) 線維症性疾患の処置のためのＴｒａｉｌレセプターアゴニスト
JP7644838B2 (ja) ＴＡＣＩ－Ｆｃ融合タンパク質を用いたＩｇＡ腎症の治療方法
KR20220027215A (ko) 다가 펩티드 컨쥬게이트를 위한 친수성 링커
US20200222548A1 (en) Synthetic bioconjugates
JP2020511543A (ja) 選択性ｔｎｆｒ１拮抗ペプチドｓｎ１０及び炎症性腸疾患におけるその使用
US20210290726A1 (en) Bioconjugates with chemically modified backbones
TWI782397B (zh) 重組全人源抗ｔｉｇｉｔ單株抗體製劑及其製備方法和用途
JP2023531683A (ja) ＣＥＢＰ－βアンタゴニストの投与及び使用方法
CA3064470A1 (en) Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof
JP2022066353A (ja) 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
TW202003577A (zh) 用於在未曾接受過治療之個體治療癌症的標靶性TGF-β抑制之給藥方案
JP7660507B2 (ja) レプチン受容体、ｇｄｆ８、およびアクチビンａに対するアンタゴニストを使用して、体重および除脂肪筋肉量を増やすための組成物および方法
AU2019288765A1 (en) Dosing regimens for targeted TGF-β inhibition for use in treating biliary tract cancer
EA041148B1 (ru) Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
TW202222345A (zh) 包含抗ｔｉｇｉｔ／ｐｄ－１雙特異性抗體的製劑及其製備方法和用途
RU2818832C2 (ru) Композиции и способы для повышения веса тела и сухой мышечной массы с применением антагонистов рецептора лептина, gdf8 и активина а
US20210009672A1 (en) Methods of treating or preventing liver fibrosis with inhibition of activins a & b
JP2020172556A (ja) デスレセプターアゴニストによる全身性硬化症の改善

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220909

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220909

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220926

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230418

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230509

R150 Certificate of patent or registration of utility model

Ref document number: 7281795

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150